![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
The T-cell Lymphoma Forum was held from 28–30 January, 2010, in Maui, HI, USA. The meeting provided a venue for clinicians and scientists to discuss the science and treatment of T-cell and natural killer (NK)-cell lymphomas. Different subtypes of T-cell and NK-cell lymphomas have different epidemiologic and clinicopathologic characteristics. T-cell and NK-cell lymphomas are more prevalent in Asian countries; however, cutaneous T-cell lymphomas are more prevalent in Western populations. The definition of pathogenetic signaling pathways and viral associations form the basis of the design for the treatment specific to these lymphomas. Therapeutic targets include surface antigen expression, cytokine signaling, epigenetic aberrations and the lymphoma microenvironment. The combination of novel therapeutic agents with chemotherapy, and the judicious use of high-dose chemotherapy and hematopoietic stem cell transplantation, may improve the outcome of patients with T-cell and NK-cell lymphomas.
Financial & competing interests disclosure
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Notes
EBV: Epstein–Barr virus; NK: Natural killer.